Jean-Pascal Machiels

Humans, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials, Phase III as Topic, Head and Neck Neoplasms, Neoplasm Recurrence, Local, Randomized Controlled Trials as Topic, Squamous Cell Carcinoma of Head and Neck, Treatment Outcome, Multicenter Studies as Topic, HNSCC, petosemtamab, LiGeR-HN, LiGeR-HN1, LiGeR-HN2, EGFR, LGR5 10.1080/14796694.2025.2511470 Post-print yes

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Background Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC.